ZYNE Annual FCF
-$23.18 M
+$10.32 M+30.81%
31 December 2022
Summary:
As of January 21, 2025, ZYNE annual free cash flow is -$23.18 million, with the most recent change of +$10.32 million (+30.81%) on December 31, 2022. During the last 3 years, it has risen by +$11.77 million (+33.67%).ZYNE Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ZYNE Quarterly FCF
-$8.43 M
-$456.30 K-5.73%
30 June 2023
Summary:
As of January 21, 2025, ZYNE quarterly free cash flow is -$8.43 million, with the most recent change of -$456.30 thousand (-5.73%) on June 30, 2023. Over the past year, it has dropped by -$542.50 thousand (-6.88%).ZYNE Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ZYNE TTM FCF
-$31.84 M
-$542.50 K-1.73%
30 June 2023
Summary:
As of January 21, 2025, ZYNE TTM free cash flow is -$31.84 million, with the most recent change of -$542.50 thousand (-1.73%) on June 30, 2023. Over the past year, it has dropped by -$6.23 million (-24.31%).ZYNE TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ZYNE Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +30.8% | -6.9% | -24.3% |
| 3 y3 years | +33.7% | +22.6% | +21.5% |
| 5 y5 years | +10.7% | +6.5% | +8.9% |
ZYNE Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | >+9999.0% | -5755.1% | >+9999.0% |
Zynerba Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$8.43 M(+5.7%) | -$31.84 M(+1.7%) |
| Mar 2023 | - | -$7.97 M(+40.0%) | -$31.30 M(+35.0%) |
| Dec 2022 | -$23.18 M(-30.8%) | -$5.69 M(-41.6%) | -$23.18 M(-8.5%) |
| Sept 2022 | - | -$9.75 M(+23.7%) | -$25.32 M(-1.1%) |
| June 2022 | - | -$7.88 M(-5391.0%) | -$25.62 M(+2.2%) |
| Mar 2022 | - | $149.00 K(-101.9%) | -$25.06 M(-25.2%) |
| Dec 2021 | -$33.51 M(-19.8%) | -$7.83 M(-22.0%) | -$33.51 M(+2.4%) |
| Sept 2021 | - | -$10.05 M(+37.0%) | -$32.72 M(-7.5%) |
| June 2021 | - | -$7.33 M(-11.6%) | -$35.36 M(-9.1%) |
| Mar 2021 | - | -$8.29 M(+17.6%) | -$38.92 M(-6.8%) |
| Dec 2020 | -$41.76 M(+19.5%) | -$7.05 M(-44.5%) | -$41.76 M(-1.1%) |
| Sept 2020 | - | -$12.69 M(+16.6%) | -$42.22 M(+4.1%) |
| June 2020 | - | -$10.88 M(-2.3%) | -$40.57 M(+11.0%) |
| Mar 2020 | - | -$11.14 M(+48.2%) | -$36.54 M(+4.6%) |
| Dec 2019 | -$34.95 M(+6.9%) | -$7.51 M(-32.0%) | -$34.95 M(+3.5%) |
| Sept 2019 | - | -$11.04 M(+61.2%) | -$33.77 M(+13.8%) |
| June 2019 | - | -$6.85 M(-28.2%) | -$29.68 M(-6.8%) |
| Mar 2019 | - | -$9.54 M(+50.6%) | -$31.85 M(-2.6%) |
| Dec 2018 | -$32.68 M | -$6.34 M(-8.8%) | -$32.68 M(-1.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$6.95 M(-22.9%) | -$33.08 M(+10.5%) |
| June 2018 | - | -$9.02 M(-13.1%) | -$29.95 M(+4.7%) |
| Mar 2018 | - | -$10.38 M(+54.0%) | -$28.62 M(+10.2%) |
| Dec 2017 | -$25.96 M(+26.3%) | -$6.74 M(+76.4%) | -$25.96 M(+4.9%) |
| Sept 2017 | - | -$3.82 M(-50.3%) | -$24.75 M(-6.8%) |
| June 2017 | - | -$7.68 M(-0.5%) | -$26.57 M(+12.8%) |
| Mar 2017 | - | -$7.72 M(+39.6%) | -$23.56 M(+14.7%) |
| Dec 2016 | -$20.55 M(+105.4%) | -$5.53 M(-1.9%) | -$20.55 M(+12.6%) |
| Sept 2016 | - | -$5.64 M(+20.6%) | -$18.25 M(+15.2%) |
| June 2016 | - | -$4.68 M(-0.6%) | -$15.85 M(+24.0%) |
| Mar 2016 | - | -$4.70 M(+45.4%) | -$12.78 M(+27.8%) |
| Dec 2015 | -$10.00 M(+181.0%) | -$3.23 M(-0.0%) | -$10.00 M(+21.4%) |
| Sept 2015 | - | -$3.23 M(+100.6%) | -$8.24 M(+28.0%) |
| June 2015 | - | -$1.61 M(-16.1%) | -$6.44 M(+24.0%) |
| Mar 2015 | - | -$1.92 M(+30.7%) | -$5.20 M(+45.9%) |
| Dec 2014 | -$3.56 M(+2857.1%) | -$1.47 M(+2.5%) | -$3.56 M(+70.4%) |
| Sept 2014 | - | -$1.43 M(+289.5%) | -$2.09 M(+218.9%) |
| June 2014 | - | -$368.30 K(+28.3%) | -$655.30 K(+128.3%) |
| Mar 2014 | - | -$287.00 K | -$287.00 K |
| Dec 2013 | -$120.40 K | - | - |
FAQ
- What is Zynerba Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Zynerba Pharmaceuticals?
- What is Zynerba Pharmaceuticals annual FCF year-on-year change?
- What is Zynerba Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Zynerba Pharmaceuticals?
- What is Zynerba Pharmaceuticals quarterly FCF year-on-year change?
- What is Zynerba Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Zynerba Pharmaceuticals?
- What is Zynerba Pharmaceuticals TTM FCF year-on-year change?
What is Zynerba Pharmaceuticals annual free cash flow?
The current annual FCF of ZYNE is -$23.18 M
What is the all time high annual FCF for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high annual free cash flow is -$120.40 K
What is Zynerba Pharmaceuticals annual FCF year-on-year change?
Over the past year, ZYNE annual free cash flow has changed by +$10.32 M (+30.81%)
What is Zynerba Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of ZYNE is -$8.43 M
What is the all time high quarterly FCF for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high quarterly free cash flow is $149.00 K
What is Zynerba Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, ZYNE quarterly free cash flow has changed by -$542.50 K (-6.88%)
What is Zynerba Pharmaceuticals TTM free cash flow?
The current TTM FCF of ZYNE is -$31.84 M
What is the all time high TTM FCF for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high TTM free cash flow is -$287.00 K
What is Zynerba Pharmaceuticals TTM FCF year-on-year change?
Over the past year, ZYNE TTM free cash flow has changed by -$6.23 M (-24.31%)